Welcome to our dedicated page for Inspire Medical SEC filings (Ticker: INSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on minimally invasive neurostimulation therapy for moderate to severe obstructive sleep apnea. These documents offer detailed insight into how Inspire reports its financial results, risks, and corporate developments.
Annual reports on Form 10-K and quarterly reports on Form 10-Q contain management’s discussion and analysis of financial condition and results of operations, along with risk factor disclosures. In these filings, Inspire describes its dependence on Inspire therapy for revenues, coverage and reimbursement considerations, competition from other therapies and technologies, reliance on third-party suppliers and contract manufacturers, international operations, information technology and cybersecurity risks, and other factors that may affect future performance.
Current reports on Form 8-K document specific material events. Recent 8-K filings have covered quarterly and annual financial results, preliminary and unaudited revenue ranges, expectations regarding the release of valuation allowances on U.S. deferred tax assets, authorization of share repurchase programs, and leadership changes such as the transition and appointment of the Chief Financial Officer. These filings often incorporate press releases and investor presentation materials by reference.
Investors can also review compensatory arrangements and executive employment agreements described in 8-K items, which outline base salary, bonus targets, equity awards, severance terms, and change-of-control provisions for senior executives. Such disclosures provide transparency into Inspire’s governance and incentive structures.
On Stock Titan, Inspire’s SEC filings are updated as they are made available on EDGAR. AI-powered summaries highlight key points from lengthy documents, helping readers quickly identify themes such as revenue drivers tied to Inspire therapy, guidance ranges, risk factors, and notable corporate actions, without replacing the need to consult the full official filings.
The Vanguard Group filed Amendment No. 4 to a Schedule 13G/A reporting its relationship to Inspire Medical Systems common stock. The filing states that, following an internal realignment effective January 12, 2026, certain Vanguard subsidiaries will report separately under SEC Release No. 34-39538. The filing discloses amount beneficially owned: 0 and percent of class: 0%.
Inspire Medical Systems is asking shareholders to vote at a fully virtual annual meeting on April 30, 2026. The proxy seeks approval to re-elect three Class II directors, ratify Ernst & Young as auditor for 2026, and hold advisory votes on executive pay and how often that say‑on‑pay vote should occur.
Shareholders are also asked to approve declassifying the board so all directors stand for annual election starting with the 2029 meeting, amend and restate the 2018 Incentive Award Plan to support broad-based equity compensation, and allow adjournment if more time is needed to pass these items. The proxy highlights 2025 revenue of $912 million, up 14% over 2024, adjusted net income of $72.1 million, adjusted diluted EPS of $2.42, and strong margins as Inspire scales its sleep apnea therapy business.
Inspire Medical Systems, Inc. is asking stockholders to approve governance and compensation proposals at its virtual 2026 Annual Meeting on April 30, 2026. The company reported full-year $912.0 million revenue for 2025, a 14% increase versus 2024, and noted adjusted net income of $72.1 million and adjusted diluted EPS of $2.42. Management highlighted delivery of strong gross margin of 85.4% and adjusted operating margin of 7.3%, the U.S. launch of the Inspire V neurostimulation system, and more than 125,000 patients treated with Inspire therapy.
The proxy includes seven proposals, notably Proposal No. 5 to phase out the classified Board with annual director elections beginning in 2029 and Proposal No. 6 to amend and restate the 2018 Incentive Award Plan to increase authorized shares. The Board recommends FOR all proposals and requests proxies for routine corporate governance, auditor ratification, and an equity plan amendment.
Inspire Medical Systems CEO Timothy P. Herbert reported equity awards and related tax withholding in company stock. He acquired 9,005 shares of common stock at $0.00 per share upon satisfaction of performance conditions tied to previously granted performance stock units. To cover taxes on this vesting, 4,010 shares were disposed of at $59.53 per share through share withholding, a non‑open‑market transaction. Herbert also received an award of 62,153 restricted stock units that will vest in three equal annual installments starting on February 20, 2027, each representing one share of common stock if he remains employed through the vesting dates. Following these transactions, he held 37,681 shares directly, and 63,658 shares were held indirectly by a family trust.
Inspire Medical Systems officer Bryan K. Phillips reported equity awards and related tax withholding transactions in company stock. He acquired 2,400 shares of common stock at no cost upon satisfaction of performance conditions tied to previously granted performance stock units and had 735 shares withheld at a price of $59.53 per share to cover taxes on that vesting. He also received two additional stock-based awards: 15,958 shares credited in connection with performance awards and 8,399 restricted stock units that will vest in three equal annual installments starting on February 20, 2027, subject to continued employment.
Inspire Medical Systems, Inc. reported that company officer Jason P. Kelly received an award of 15,958 shares of common stock in the form of restricted stock units. The award was granted at no cash cost.
The RSUs vest in three equal annual installments starting on February 20, 2027, and each unit converts into one share of common stock if Kelly remains continuously employed through the applicable vesting date. Following this grant, he directly holds 19,948 shares of Inspire Medical Systems common stock.
Inspire Medical Systems reported that Chief People Officer Melissa Mann acquired 15,958 shares of common stock through a grant of restricted stock units. These RSUs vest in three equal annual installments starting on February 20, 2027. Each RSU converts into one common share if she remains employed through each vesting date.
Inspire Medical Systems executive Weatherby Carlton reported equity compensation changes involving the company’s common stock. On February 20, 2026, he acquired 2,196 shares at no cost following satisfaction of performance conditions on previously granted performance stock units, and 672 shares were withheld at $59.53 per share to cover taxes on that vesting.
On the same date, he also received additional stock awards totaling tens of thousands of shares at no cost, including restricted stock units that vest in three equal annual installments beginning February 20, 2027, contingent on his continued employment. After these transactions, his directly held common stock balance increased, even after the tax-withholding disposition.
Inspire Medical Systems officer John Rondoni reported equity compensation and related tax withholding in company stock. He acquired 2,400 shares of common stock at no cost upon satisfaction of performance conditions tied to earlier performance stock units, and 15,958 additional shares through a new stock award.
To cover taxes from vesting of a performance stock unit award, 735 shares were withheld at a price of $59.53 per share. After these transactions, he directly owned 14,548 shares following the tax withholding and 30,506 shares following the new restricted stock unit award, which will vest in three equal annual installments starting February 20, 2027.